See more : SHARPLINE BROADCAST LIMITED (SHARPLINE.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Cantabio Pharmaceuticals, Inc. (CTBO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cantabio Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Electra Private Equity Plc (ELTA.L) Income Statement Analysis – Financial Results
- Shenglong Splendecor International Limited (8481.HK) Income Statement Analysis – Financial Results
- Zuari Agro Chemicals Limited (ZUARI.NS) Income Statement Analysis – Financial Results
- Crayon Group Holding ASA (CRAYF) Income Statement Analysis – Financial Results
- Auto Italia Holdings Limited (0720.HK) Income Statement Analysis – Financial Results
Cantabio Pharmaceuticals, Inc. (CTBO)
About Cantabio Pharmaceuticals, Inc.
Cantabio Pharmaceuticals, Inc., a preclinical stage biotechnology company, focuses on the research, development, and commercialization of novel therapies for Parkinson's disease (PD), Alzheimer's disease (AD), and other related diseases. Its lead programs include CB101, a DJ-1 targeting small molecule pharmacological chaperone for use in the treatment of PD; CB201, a CNS penetrant engineered DJ-1 protein for use in the treatment of PD; CB301, a Tau protein targeting small molecule pharmacological chaperone for use in the treatment of AD; and CB401, an Aß targeting small molecule pharmacological chaperone for use in the treatment of AD. The company has a collaboration agreement with Luxembourg Institute of Health to research the therapeutic targeting of the DJ-1 - protein to treat immune associated diseases. The company was founded in 2009 and is based in Palo Alto, California.
Source: https://incomestatements.info
Category: Stock Reports